The Art of Innovation: How to Become a "Partner of Choice" (Interview)
Copyright by Stephan Klaschka 2010-2025
The Challenge
Over time, large organizations tend to lose their innovative edge (see also Why mature organizations can’t innovate). Their research hardly leads to the discovery of new products in their field of business. In search of new assets for their development pipeline to bring new drug products to the market that will help patients with yet unmet medical needs, they increasingly rely on startups and research entrepreneurs to provide discoveries they can buy or in-license or whom to partner with.
However, startups and entrepreneurs can find it challenging to work with large organizations that resemble complex machinery. Lengthy, comprehensive, and sometimes convoluted processes, with red tape and bureaucracy throughout, strain patience and can easily obstruct the much-needed, mutual collaboration.
So, a few years back I was interviewed together with esteemed colleagues from other pharmaceutical companies on a challenging question for the industry:
How can pharma companies ensure they’re first in line when researchers and entrepreneurs come knocking?
Read the interview here on how large pharmaceutical companies strive to position themselves to become attractive ‘partners of choice’.